A Journey of Three Decades
30 Years of Innovation at INTERmedic
Discover how we have revolutionized the healthcare industry over the past 30 years with our innovative laser solutions.
Key Milestones in Our History
From our beginnings to becoming an industry benchmark, here are the moments that defined our path.
1998
INTERmedic is born
We started our activity after the acquisition of Frank Line Medical Systems, which was awarded by the Spanish government for developing the first CO2 laser in the country.
2001
Development of the PL3D™ Laser
We developed the PL3D™ laser for percutaneous 980 nm laser disc decompression. This development was carried out in collaboration with the Traumatology Service of the University of Florence and represents the world’s first publication of the technique using this wavelength.
2002
Innovation in Placental Anastomosis Treatments
We developed a specific laser for placental anastomosis treatments in collaboration with the Fetal Medicine Department of the Virgen de las Nieves University Hospital. On January 17, 2003, we were able to see the results of this project, marking a milestone in fetal medical care.
2003
Innovation Leadership
We developed the technique for transcanicular laser dacryocystorhinostomy in collaboration with the Ophthalmology Department of the Cristo Rey Hospital. This technique, born in Spain, stands out as the first publication worldwide in this field. In addition, at INTERmedic, we extend our product portfolio to different medical divisions, including Vascular, Ophthalmology, Surgery and Urology.
2004
International Expansion
We began a process of international expansion into new markets, with the goal of bringing our innovative medical solutions to more healthcare professionals and patients around the world. This strategic growth will enable us to strengthen our global presence and continue to improve the quality of medical care internationally.
2005
Launching of the Eureka ENDOlaser 1500 Project
We launched the Eureka ENDOlaser 1500 project, financed by the European Union, which enabled the development of a new wavelength for endovenous treatments. The first tests were carried out at the Ruber International Hospital. Today, this wavelength has become the world standard in endovenous technique, and we have obtained the world’s first publication on this innovative technique.
2006
FDA Clearance for our Surgical Line and First Prize from the Spanish Academy of Dermatology.
We obtained FDA Clearance for our surgical line, consolidating our commitment to quality and safety in the development of medical technologies. In addition, we have been awarded the first prize of the Spanish Academy of Dermatology. In collaboration with the University Hospital of León, we developed a revolutionary technique for the treatment of thick basal cell carcinoma and hidradenitis suppurativa. This innovative technique has been presented in the world’s first publication in the American Journal of Dermatology and the British Journal of Dermatology.
2010
We developed an innovative technique for vaporization and enucleation of the prostate.
We developed a new technique for prostate vaporization and enucleation using the SST200 diode laser, a high-power 980 nm device that uses a curved fiber instead of a side-shot. This technique has been developed in Spain at Clínica Cemtro and has been endorsed by several international publications, consolidating our commitment to innovation in the treatment of prostate health.
2013
Obtained CFDA Certification for its Surgical Lasers and Launched PODYLAS™.
We obtained CFDA certification for our surgical lasers in China, reaffirming our commitment to quality and safety in the development of medical technologies. Together with the Universitat de Barcelona, we developed PODYLAS™, a 1,064 nm solid-state podiatric laser designed to be a multidisciplinary device with diverse podiatric applications. This innovative technology has resulted in the first international publication on its use, highlighting our focus on research and development.
2014
Developed First 16-Channel Laser for Photodynamic Prostate Cancer Therapy and Launched Gynelase™ for Gynecologic Treatments
We developed and manufactured the world’s first laser with 16 channels to treat prostate cancer using photodynamic therapy (PDT). These devices have been used in a multicenter study of 400 cases, leading to EMA approval of both the drug and the technique. In addition, we launched Gynelase™, a fractional CO2 laser designed for the treatment of stress urinary incontinence (SUI), genitourinary syndrome of menopause (GSM), cervical pathologies, condyloma vaporization and labiaplasty, thus expanding our solutions in the gynecological field.
2015
We developed together with the University Hospital of Elche the i-PDT laser for the treatment of anal fistulas.
In collaboration with the proctology service of the Hospital Universitario de Elche, we developed the i-PDT laser, an innovative technique for the intralesional treatment of anal fistulas. This new technique has shown a high success rate in its preliminary studies and is considered a pioneering treatment worldwide, supported by the first worldwide publication on its application.